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http://dx.doi.org/10.1016/j.numecd.Abstract Background and aims: The ESC/ESH guidelines for arterial hypertension recom-
mend using statins for patients with high cardiovascular (CV) risk for both secondary and pri-
mary prevention. A recent meta-analysis, combining previous studies on statins, concluded
that they are associated with a 9% increased risk of incident type 2 diabetes mellitus (DM).
There is no information on whether statins increase incidence of DM in primary prevention.
Method and results: We evaluated risk of incident DM in relation to statin prescription in 4750
hypertensive, non-diabetic outpatients (age 58.57  9.0 yrs, 42.3% women), from the Campa-
niaSalute Network, without chronic kidney disease more than grade 3, free of prevalent CV dis-
ease and with at least 12 months of follow-up. DM was defined according to ADA criteria. At the
end of follow-up period (55.78  42.5 months), 676 patients (14%) were on statins. These pa-
tients were older (62.54  7.3 vs 57.91  9.1 yrs; p < 0.0001), more often female (49% vs
41.2%; p Z 0.0001), with higher in i t ia l tota l cho lestero l (217.93  44.3 vs
205.29  36.6 mg/dl), non-HDL cholesterol (167.16  44.5 vs 155.18  36.7 mg/dl) and triglyc-
erides (150.69  85.2 vs 130.98  72.0 mg/dl; all p < 0.0001) than patients no taking statins,
without other differences in clinical and laboratory characteristics. At the end of follow-up,
prevalence of DM was 18.1% among patients on statins and 7.2% among those without lipid-
lowering therapy (p < 0.0001). However, incident DM was 10.2% in patients on statins and
8.7% in those free of statin therapy (NS).art by grant AIFA: Italian agency of drugs. Supported in part by grant: AIFA/FARM5STRH9.
of Clinical and Experimental Medicine, Federico II University Hospital, via S. Pansini 5 bld 1, 80131
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1102 R. Izzo et al.Conclusion: In real-life outpatient environment, statin prescription for primary prevention is
not associated with increased risk of incident DM.
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Incidence of type 2 diabetes mellitus (DM) is increasing
rapidly [1] and even high fasting glucose is associated with
increased cardiovascular (CV) risk [2]. High blood pressure
is also one of major causes of CV disease [3] and arterial
hypertension is common in patients with DM. The rela-
tionship between hypertension and DM is complex; DM is
a predictor of hypertension [4] and also occurs more fre-
quently in patients with arterial hypertension [4], partic-
ularly in patients in whom antihypertensive therapy does
not control blood pressure [5]. Because the frequent
occurrence of hypertension combined with DM further in-
creases the absolute risk of CV death [6], particular
attention should be paid to the occurrence of DM in hy-
pertensive patients in order to prevent rising CV risk.
Current guidelines for the management of arterial hy-
pertension recommend that treatment with HMG-CoA
reductase inhibitors (statins) be prescribed in all hyper-
tensive subjects with diabetes or with high or very high CV
risk, for both primary and secondary prevention [7].
Opposing to this recommendation, a meta-analysis has
reported that statin therapy might be associated with 9%
increase in incident DM [8], a finding that raised alarm. In
this meta-analysis there was a substantial proportion of
patients with coronary heart disease likely taking high
doses of statins, according to recent guidelines and it is now
becoming more evident that treatment with intensive doses
of statins is associated with higher incidence of new-onset
DM than low-to- moderate dose as prescribed for primary
prevention [9].
It is still unclear whether statin therapy is associated
with a generalized tendency to an increase in diabetes risk
in a real-life clinical context and, specifically, there is no
direct information about the problem whether statins can
still be safely prescribed for primary CV prevention, espe-
cially in hypertensive patients who are at risk of developing
DM.
Accordingly, this study has been designed to verify
whether in a large cohort of hypertensive, non-diabetic
patients, followed up in a tertiary care setting and sub-
jected to a program of primary prevention, statin therapy is
independently associated with an increased probability of
new-onset DM.Methods
Participants
The cohort of the CampaniaSalute Network was analyzed.
Details on this cohort have been previously reported [10].
Briefly, beginning 1997, a network has been generatedamong the Hypertension Center of the Federico II Univer-
sity Hospital (Naples, Italy), 23 Community Hospital-based
Hypertension Clinics and 60 General Practitioners from
the Campania district in Southern Italy (CampaniaSalute
Network) including over 12,000 cardiovascular (CV) pa-
tients, of whom 10,254 had arterial hypertension. Among
hypertensive subjects at the time of the first examination
in the outpatient clinic, 7097 were free of prevalent CV
disease [10] (previous myocardial infarction or angina or
procedures of coronary revascularization, stroke or tran-
sitory ischemic attack, congestive heart failure or chronic
kidney disease more than grade 3 (glomerular filtration rate
[GFR] < 30 ml/min/1.73 m2) [11]). Prevalent CV disease
was excluded by an ad-hoc committee in the Hypertension
Center, and based on patient’s history and clinical exam,
contact with the referring general practitioner or commu-
nity hospital center and clinical records documenting the
occurrence of disease [12].
Criteria for selection in the present study included the
availability of at least 12 months of follow-up and the
absence of diabetes at the time of the first visit in the
Hypertension Clinic. From the initial population, 2347 pa-
tients were excluded: 1237 had a follow-up period or
duration of statin therapy shorter than 1 year, 724 (i.e. 10%)
were lost to follow-up, 386 had prevalent diabetes mellitus.
Thus, 4750 Caucasian, non-diabetic hypertensive patients,
(42.3% women, age 58.6  9.0 years) free of prevalent CV
disease were analyzed, who had been followed up over
55.8  42.5 months.
All patients on statins had received the medication over
at least one year without any suspension for the entire year
before the end of follow-up. Statin therapy was censored at
the time of the last visit before diagnosis of diabetes for
patients with incident diabetes and at the time of the last
available visit for patients without incident diabetes. Pre-
scribed statins were: simvastatin 20 or 40 mg/die, ator-
vastatin 10 or 20 mg/die, rosuvastatin 10 mg/die.
The data-base generation of the CampaniaSalute Net-
work was approved by the Federico II University Hospital
Ethic Committee. Signed informed consent for the use of
data for scientific purposes was obtained from all the
participants.
Laboratory tests and definitions
Fasting plasma glucose and lipid profiles were measured by
standard methods. Non-HDL cholesterol was also calculated
as the difference between total and HDL cholesterol.
Reported medical diagnostic codes for diabetes and pre-
scriptions of oral hypoglycaemic drugs or insulin were used to
identify prevalent cases of diabetes. Diagnosis of prevalent
and incident diabetes was also confirmed by fasting plasma
glucose  126 mg/dl, according to ADA guidelines [13].
Statins therapy and incident diabetes 1103GFR was estimated from serum creatinine by the modi-
fied MDRD equation [11]. Systolic and diastolic blood pres-
sure (BP) were measured at each visit by standard
sphygmomanometer after 5 min in the sitting position, ac-
cording to European Society of Hypertension/European
Society of Cardiology guidelines [7]. Body mass index (BMI)
was calculated at each visit. Number and type of prescribed
antihypertensive medications were recorded for all par-
ticipants. Classes of medications were categorized as fol-
lows: anti-RenineAngiotensin System (Anti-RAS: including
ACE inhibitors and/or Angiotensin AT1 receptor antago-
nists), calcium-channel blockers (CCB), b-blockers, di-
uretics, according to their overall use during the individual
follow-up, based on the frequency of prescription during
the various control visits. At each control visit, prescription
of statins was also recorded.
Statistical analysis
Data were analyzed using SPSS (version 17.0; SPSS, Chicago,
IL) and expressed as mean  1 standard deviation. All
variables deviating from normal distribution were log-
transformed before parametric statistics. Patients with or
without at least one year of statin therapy were initially
compared using t-tests. Categorical variables were com-
pared using chi-square statistics.
Hazard functions for incident DM were generated by Cox
regression analysis comparing participants taking or not
taking statins, adjusting for covariates, including BMI and
all variables that significantly differed between the sub-
groups in exploratory statistics. These variables included:
age, sex, BMI, fasting plasma glucose, duration of hyper-
tension, BP, heart rate, non-HDL cholesterol and tri-
glycerides at the time of the first visit. Cox regression was
also repeated by including classes of antihypertensive
medications and number of prescribed antihypertensiveTable 1 Initial characteristics of the study population (by stati
No statins
N Z 4074
Age (years) 57.91  9.1
Gender (% women) 41.2%
BMI (kg/m2) 27.74  4.2
Duration of hypertension (years) 5.44  6.3
Family history of diabetes 29.3
Follow-up time (months) 54.99  42.0
Systolic BP (mmHg) 141.76  17.
Diastolic BP (mmHg) 90.21  10.3
Heart rate (bpm) 74.89  11.5
Fasting plasma glucose (mg/dl) 95.47  12.4
Creatinine (mg/dl) 0.96  0.2
GFRMDRD (ml/min/1.73 m
2) 79.99  17.3
Cholesterol (mg/dl) 205.29  36.
HDL cholesterol (mg/dl) 50.07  12.6
Non-HDL cholesterol (mg/dl) 155.18  36.
Triglycerides (mg/dl) 130.98  72.
Abbreviations: BMI: body max index, BP: blood pressure, GFR: glome
HDL: high-density lipoprotein.medications. To account for therapy, single classes of
antihypertensive medications were dichotomized according
to their overall use during the individual follow-up. Thus, as
previously reported [5], antihypertensive medications that
were prescribed for more than 50% of the total number of
control visits were censored in the analysis. Two-tailed
p < 0.05 was considered statistically significant. A post-
hoc “compromise power analyses” (by GPower 3.0.10),
based on the 9% difference in incidence found in the Sattar
meta-analysis, the size of the two subpopulations and an
optimized b/a ratio (i.e. b Z 0.80 and a Z 0.05) was run,
confirming a one-tail a Z 0.052803 and a b Z 0.847124.
Results
Among the 4750 hypertensive outpatients included in the
analysis, 42.3% were women; 39.7% were obese and 14.2%
(n Z 676) were on statin treatment.
Patients on statins were older, more often women, with
longer duration of hypertension and follow-up period. At
the time of initial visit, they had lower diastolic BP and
heart rate, higher plasma levels of fasting glucose, total,
non-HDL cholesterol and triglycerides (Table 1, all
0.005 < p < 0.0001). No difference was found in BMI, cre-
atinine, GFR and HDL cholesterol.
At the time of the last visit before diagnosis of DM, pa-
tients on statins had lower systolic and diastolic BP, heart
rate, GFR, total and non-HDL cholesterol, and higher levels
of fasting glucose, HDL cholesterol and triglycerides than
patients not on statin therapy (Table 2, 0.05 < p < 0.0001).
Table 3 shows that, before of diagnosis of DM, the
number of prescribed antihypertensive medications was
higher, and the single prescriptions of anti-RAS, diuretics
and CCB more frequent in patients on statins than in those
not taking statins (0.03 < p < 0.0001), whereas no differ-
ence was found for b-blockers.n prescription during the follow-up).
Statins
N Z 676
p
62.54  7.3 0$0001
49% 0.0001
27.47  3.9 NS
7.20  6.9 0.0001
29.1 NS
60.49  45.1 0.002
1 141.85  17.3 NS
88.78  10.1 0.001
73.56  11.3 0.005
96.62  12.3 0.026
0.94  0.2 NS
78.35  17.0 NS
6 217.93  44.3 0.0001
50.7  12.6 NS
7 167.16  44.5 0.0001
0 150.69  85.2 0.0001
rular filtration rate, MDRD: modification of diet in renal disease,
Table 2 Characteristics of the study population at the
time of last visit in the absence of diabetes.
No statins
N Z 4074
Statins
N Z 676
p
BMI (kg/m2) 27.85  4.1 27.80  4.0 NS
Systolic BP (mmHg) 132.65  18.3 131.16  15.9 0.046
Diastolic BP (mmHg) 82.59  14.0 79.22  8.9 0.0001
Heart rate (bpm) 72.71  18.3 70.47  10.5 0.002
Fasting plasma
glucose (mg/dl)
95.47  12.4 96.62  12.3 0.026
Creatinine (mg/dl) 0.96  0.3 0.94  0.2 NS
GFRMDRD (ml/min/
1.73 m2)
79.99  17.3 78.35  17.0 0.024
Cholesterol (mg/dl) 200.90  4.5 192.38  39.9 0.0001
HDL cholesterol
(mg/dl)
50.34  12.8 52.06  13.4 0.001
Non-HDL cholesterol
(mg/dl)
150.55  44.1 140.31  38.6 0.0001
Triglycerides
(mg/dl)
129.41  67.2 137.77  65.7 0.003
Abbreviations: BMI: body max index, BP: blood pressure, GFR:
glomerular filtration rate, MDRD: modification of diet in renal
disease, HDL: high-density lipoprotein.
Figure 1 Incidence of type 2 diabetes in relation to statin
therapy prescribed before diagnosis, adjusted for age, gender,
duration of hypertension and baseline parameters (see Table 4).
Table 4 Cox model showing baseline predictors of new-
onset type 2 diabetes in hypertensive, non-diabetic pa-
tients. The model includes age, gender, use of statins
before diagnosis of diabetes, duration of hypertension and
baseline parameters.
p HR 95% CI
Statin before diagnosis
of DM (y/n)
0.832 1.03 0.79e1.35
Age (years) 0.002 1.02 1.01e1.04
Initial triglycerides (10 mg/dl) 0.000 1.02 1.01e1.03
Initial diastolic BP (5 mmHg) 0.290 1.03 0.98e1.07
1104 R. Izzo et al.At the end of follow-up, prevalence of diabetes was 18.1%
in patients under statin therapy, compared to 7.2% in those
without statin therapy (RR Z 2.85; 95% CI Z 2.28e3.56;
p < 0.0001), but the unadjusted risk of incident diabetes in
relation of prescribed statin therapy before diagnosis of
diabetes was not significantly different, with 10.2% inci-
dence among patients taking statins and 8.7% in patients
free of the medication (RRZ 1.02, pZ 0.192).
In a Cox model, adjusted for gender, duration of hy-
pertension, initial diastolic BP, heart rate, plasma glucose,
total and non-HDL cholesterol and triglycerides, statin
prescription was confirmed to be not associated with inci-
dent DM (Fig. 1). In this Cox model, predictors of incident
diabetes during follow-up were older age, higher BMI,
higher initial plasma glucose, total cholesterol and tri-
glycerides, and duration of hypertension (Table 4). The Cox
model was repeated after addition of classes of anti-
hypertensive medications and number of prescribed anti-
hypertensive medications confirmed exactly the model
displayed in Table 4 with negligible variations of co-
efficients of regression (not shown).Table 3 Frequency of antihypertensive prescription in
>50% of visit.
No statins
N Z 4074
Statins
N Z 676
p
Thiazides (%) 39.3 49.6 0.032
b-Blockers (%) 30.7 30.9 NS
ANTI-RAS (%) 63.2 78 0.001
CCB (%) 24.9 32.1 0.001
Mean number
of medications
1.58 1.87 0.0001Discussion
In contrast to what has been suggested in a metanalysis [8],
this study demonstrates that statin therapy, at least per-
formed at the doses used for primary prevention, is not
associated with incident DM. We analyzed a representative
and relatively unselected large cohort of hypertensive pa-
tients free of prevalent CV disease and followed in ourGender (m/f) 0.108 1.19 0.96e1.48
Initial BMI (kg/m2) 0.000 1.054 1.03e1.08
Duration of hypertension
(5 years)
0.020 1.10 1.02e1.16
Initial HR (bpm) 0.659 1.00 0.99e1.07
Initial fasting glucose (mg/dl) 0.0001 1.46 1.41e1.55
Initial cholesterol (5 mg/dl) 0.025 0.95 0.93e0.99
Initial non-HDL cholesterol
(mg/dl)
0.284 1.01 1.00e1.01
Abbreviations: DM: type 2 diabetes mellitus, BMI: body max
index, BP: blood pressure, HR: heart rate, HDL: high-density
lipoprotein.
Statins therapy and incident diabetes 1105tertiary care unit. This finding is consistent with another
meta-analysis showing that the risk of incident DM is asso-
ciated with high-dose statin therapy (usually given for
secondary prevention programs) rather than lowemoderate
dose [9].
As largely expected, in cross-sectional analyses, statins
were more often prescribed in patients with prevalent DM
and high CV risk. The strength of this analysis is the
examined context, which reflects the physician behavior in
real life. Because all patients of the CampaniaSalute net-
work are referred to our Center, the risk of a selection bias
is minimized. Despite the improvement in CV prevention
and the reduction of mortality and morbidity for CV events
during the past decades, public health burden due to CV
risk remains high. Statin therapy is generally considered to
be effective and safe in reducing CV events [14,15].
Despite the consolidated evidence of lack of serious
major side effects [9,16e18], several large trials [19e22]
have reported an association between statin therapy and
development of diabetes, thus raising doubts on this par-
ticular metabolic aspect of statin safety. However, this
association was not confirmed in other intervention studies
[23,24]. In addition, in a relatively tiny sample of hyper-
lipidemic patients, including patients on high-dose statins,
with or without coronary heart disease, a significant,
though modest, increase in circulating insulin levels was
seen after 6 weeks of treatment in the absence of deteri-
oration of glucose control [25].
The relevance of the problem and the contradictory
findings led to calls for a systematic exploration of the
possible effect of statin therapy on incident diabetes [26].
To contribute clarifying the uncertainty produced by
those contrasting results, a meta-analysis was performed
taking into account published and unpublished data from
large placebo-controlled and standard-care-controlled
statin trials. Results from this meta-analysis suggested
that statin therapy could be in fact associated with an
overall tiny 9% increased risk for incident diabetes [8] in
a context, however, in which all the other potential con-
founders could not be considered, including prevalence of
CV disease, different med dose, and co-morbidities.
In contrast, in our cohort all patients were free of
prevalent CV disease and received statins at lowemoderate
doses, as suggested by the usual clinical practice, and all
potential confounders were taken into account. Therefore,
our study is the first direct evidence that in a large, rela-
tively unselected clinical sample of hypertensive, non-
diabetic outpatients, free of prevalent CV disease and
subjected to a primary prevention program, therapy with
statins is not associated with increased risk of new-onset
DM, also when major risk factors and confounders are
considered over a follow-up of 1e10 years. The strength of
this analysis is in the clinical characteristics of this out-
patient population, which can be easily generalized in
similar contexts.
The different prevalence in diabetes rates recorded
cross-sectionally at the end of follow-up between the two
subpopulations confirms that statin was given mostly to
patients with more severe and long-standing hypertension
and worse metabolic profile, thus at higher risk of diabetes
[5] and, it is, therefore, relevant that despite the increased
risk of diabetes and after accounting for the differentinitial risk-profile, statins do not exhibit independent effect
on incident diabetes, at least at the doses we used for our
primary prevention program.
The information, is, therefore, mostly applicable to
hypertensive population. This type of analysis, in this
context reflecting real behavior of doctors, is increasingly
valorized by the widely emerging position of medical re-
searchers and even political leaders, highlighting the un-
successful translation of a number of findings from research
papers into medical practice and personal physician’s
behavior [27].
The second strength of our study is that our design is
prospective, and therefore scarcely affected by selection
bias. Rather, a potential bias, favoring the possible rejec-
tion of our null hypothesis was the tendency to prescribe
statin therapy in patients who have a greater risk of
developing diabetes, as evident in our cross-sectional
analysis.
Sometimes meta-analysis reports are contradicted by
large population studies [28], due to the known limitations
[29e32]. Focusing the attention on the reported meta-
analysis [8], it is even important to highlight that only
two of the 13 analyzed studies reported a statistical asso-
ciation between statin therapy and incident DM, and one of
the two was also the largest. Secondly, many trials reported
opposite results even using the same type of statin [8,23].
Thirdly, in the Sattar’s meta-analysis, the 95% confidence
interval of odds ratios has been used, whereas the 99%
confidence interval could be preferentially estimated, as it
has been suggested [33]. Thus, the small difference (9%) in
the incidence of DM could have been occurred by chance.
Lastly, most trials in this meta-analysis analyzed clinical
situation requiring use of high-dose statins, in contrast with
our study performed in a clinical context of primary pre-
vention program.
Our study offsets, at least in part, the lack of trials
specifically addressed to evaluate the effect of long-term
use of lowemoderate dose statin on incident diabetes in
primary prevention programs.
In our hypertensive cohort, a number of risk factors
confirmed to be predictors of incident DM [5], including
older age, initial impaired fasting glucose and lipid profile,
and duration of hypertension. Furthermore the results of
the present study suggest that statin therapy, at the doses
used for primary prevention programs, is safe and does not
increase the risk of incident DM. Our results also indicate
that in a real-life context, prescriptions are more frequent
in patients after development of diabetes and in those at
high risk of diabetes. Our findings are mostly applicable to
hypertensive population, in a real-life context reflecting
real behavior of doctors. This context is increasingly
valorized by the widely emerging position of medical re-
searchers and even political leaders, highlighting the un-
successful translation of a number of findings from research
papers into medical practice and personal physician’s
behavior [27].Limitations
A potential limitation of the study, common in studies
performed using registries in real-life contexts, is that
1106 R. Izzo et al.diagnosis of diabetes was based on fasting glucose levels
only, as we do not have oral glucose tolerance test as
a primary work-up test in all patients. However, because
our purpose was to select patients with normal glucose
metabolism, probably selection based on impaired fasting
glucose is more conservative than selection based on glu-
cose tolerance test, which appears to be a higher level of
metabolic abnormality [34].
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.numecd.2012.11.002.References
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